Embryonic stem cells (ESC) seem to have the potential to become an alternative source of cells for bone marrow transplantation, with a new study showing that they can be used to created functional immune system blood cells.
The study, published online in journal Blood, offers new hope to patients with severe blood and immune disorders.
Researchers at the University of Iowa Hospitals and Clinics say that one of the biggest limitations of traditional transplants—which use bone marrow, umbilical cord blood, and peripheral blood from donors—is that the antigens on the surface of donated cells must be compatible with those of the patient to prevent rejection.
This is where the advantage of using embryonic stem cells comes into picture, say the researchers.
According to them, embryonic stem cells have low levels of these antigens and may therefore be less likely to provoke a defensive reaction by the patient’s body. Thus, even when patients do not find suitably matched donors, they may still be able to receive transplants.
Previous studies had shown that mouse embryonic stem cells could be coaxed to form blood-forming hematopoietic cells by introducing into them a protein called HOXB4, known for its unique ability to greatly enhance cell proliferation.
In the latest study, a team of scientists from Iowa, Taiwan, and Germany used HOXB4-containing ESCs to engraft the bone marrow and rescue mice that genetically lacked any immune system and had been irradiated to destroy their bone marrow.